Literature DB >> 24815140

Thrombomodulin administration attenuates ischemia-reperfusion injury of the remnant liver after 70% hepatectomy in rats: simulated model of small-for-size graft in living donor liver transplantation.

A Tanemura1, N Kuriyama2, Y Azumi2, I Ohsawa2, M Kishiwada2, S Mizuno2, M Usui2, H Sakurai2, M Tabata2, S Isaji2.   

Abstract

BACKGROUND: Hepatic ischemia-reperfusion injury (IRI) is a serious complication affecting liver function and postoperative course after liver transplantation. Thrombomodulin (TM) has been known to have anticoagulant and anti-inflammatory activities exerting a cytoprotective effect. We evaluated the cytoprotective effect of recombinant human soluble TM (rhsTM) on the remnant liver exposed to IRI after 70% hepatectomy in rats, which was the simulated model of small-for-size graft in living donor liver transplantation.
MATERIALS AND METHODS: A Wistar rat underwent 70% hepatectomy followed by 20-minute IRI for the remnant liver. rhsTM (1 mg/kg) (TM group) or saline (control group) was intravenously administered 30 minutes before operation.
RESULTS: Alanine aminotransaminase levels were more significantly decreased during the 24 hours after operation in the TM group than in control group, especially at 6 hours. Intrahepatic infiltration of macrophages/monocytes (ED-1 immunohistochemical staining) at 6 hours was significantly decreased in the TM group compared to the control group. The number of proliferating cell nuclear antigen-positive cells at 12 hours (hepatocyte proliferation) was significantly higher in the TM group than in the control group; although liver weight 7 days after operation did not differ between the two groups. Hepatocyte apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, also known as TUNEL assay) at 24 hours was more significantly diminished in the TM group than in the control group.
CONCLUSION: These results suggest that rshTM attenuates hepatocyte injury through its anti-inflammatory effect, and promotes hepatocyte proliferation in the reduced-size liver exposed to hepatic IRI.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24815140     DOI: 10.1016/j.transproceed.2013.11.128

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury.

Authors:  Ronald Carnemolla; Carlos H Villa; Colin F Greineder; Sergei Zaitsev; Kruti R Patel; M Anna Kowalska; Dmitriy N Atochin; Douglas B Cines; Don L Siegel; Charles T Esmon; Vladimir R Muzykantov
Journal:  FASEB J       Date:  2016-11-11       Impact factor: 5.191

Review 2.  Pre-conditions for eliminating mitochondrial dysfunction and maintaining liver function after hepatic ischaemia reperfusion.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2017-03-16       Impact factor: 5.310

3.  Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform.

Authors:  Ahmer M Hameed; David B Lu; Heather Burns; Nicole Byrne; Yi Vee Chew; Sohel Julovi; Kedar Ghimire; Negar Talaei Zanjani; Chow H P'ng; Daniel Meijles; Suat Dervish; Ross Matthews; Ray Miraziz; Greg O'Grady; Lawrence Yuen; Henry C Pleass; Natasha M Rogers; Wayne J Hawthorne
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

4.  The lectin-like domain of thrombomodulin is a drug candidate for both prophylaxis and treatment of liver ischemia and reperfusion injury in mice.

Authors:  Junya Kawasoe; Yoichiro Uchida; Tomoyuki Miyauchi; Kentaro Kadono; Hirofumi Hirao; Kenichi Saga; Takeshi Watanabe; Shugo Ueda; Hiroaki Terajima; Shinji Uemoto
Journal:  Am J Transplant       Date:  2020-09-24       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.